| P50 | author | Malgorzata Szafarz | Q64515513 |
| | Kinga Kwiecinska | Q90964014 |
| | Miroslaw Bik-Multanowski | Q91298386 |
| | Walentyna Balwierz | Q102361240 |
| | Malgorzata Czogala | Q115363572 |
| | Szymon Skoczeń | Q125172866 |
| P2093 | author name string | Anna Madetko-Talowska | |
| | Konrad Stepien | |
| | Aleksandra Wieczorek | |
| | Tomasz Klekawka | |
| | Karol Miklusiak | |
| | Magdalena Cwiklinska | |
| | Magdalena Rej | |
| | Agnieszka Lazarczyk | |
| | Katarzyna Pawinska | |
| | Przemyslaw Halubiec | |
| P2860 | cites work | Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate? | Q50997349 |
| | Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. | Q51996061 |
| | Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. | Q53165185 |
| | Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia. | Q53517804 |
| | Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. | Q54372512 |
| | Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. | Q54374230 |
| | Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. | Q54566243 |
| | Genetic Profile and Clinical Implications of Hepatoblastoma and Neuroblastoma Coexistence in a Child | Q64076272 |
| | Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia | Q77891734 |
| | Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis | Q81133992 |
| | Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia | Q84541179 |
| | Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice | Q85657059 |
| | Genetic Signature of Acute Lymphoblastic Leukemia and Netherton Syndrome Co-incidence-First Report in the Literature | Q89497255 |
| | Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients | Q90324412 |
| | Pharmacogenetic Variants in MTHFR Gene are Significant Predictors of Methotrexate Toxicities in Bangladeshi Patients With Acute Lymphoblastic Leukemia | Q92298687 |
| | Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells | Q28476416 |
| | International incidence of childhood cancer, 2001-10: a population-based registry study. | Q30061737 |
| | Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma | Q33384217 |
| | Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma | Q33395001 |
| | Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population | Q33395136 |
| | Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia | Q33395660 |
| | Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia | Q33398162 |
| | The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number | Q33931844 |
| | Role of thymidylate synthetase activity in development of methotrexate cytotoxicity | Q33982869 |
| | Pharmacogenetics of methotrexate | Q35911142 |
| | Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. | Q36402208 |
| | Regulation of p53 expression by thymidylate synthase | Q36451021 |
| | Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma | Q36789432 |
| | Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. | Q37369929 |
| | Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country | Q37978262 |
| | Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL. | Q38506522 |
| | Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia. | Q40362166 |
| | Pharmacogenetics of outcome in children with acute lymphoblastic leukemia | Q41973110 |
| | Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia | Q42704887 |
| | Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. | Q42746762 |
| | Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia | Q43221788 |
| | Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism | Q43648037 |
| | Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia | Q44201573 |
| | Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia | Q44473547 |
| | Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia | Q44547442 |
| | Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene | Q45323271 |
| | Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia | Q46410865 |
| | G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism | Q46554650 |
| | Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia | Q46681182 |
| | DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. | Q46838407 |
| | Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma | Q46931257 |
| | MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. | Q46931731 |
| | MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells | Q49977636 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | methotrexate | Q422232 |
| | lymphoblastic leukemia | Q18553852 |
| P304 | page(s) | 307 | |
| P577 | publication date | 2020-06-16 | |
| P1433 | published in | Frontiers in pediatrics | Q27725038 |
| P1476 | title | Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate | |
| P478 | volume | 8 | |